Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LASA | NSE
0.21
2.73%
Healthcare
Drug Manufacturers-Specialty & Generic
31/03/2024
05/06/2026
7.91
7.80
7.95
7.50
Lasa Supergenerics Limited engages in the research manufacture and marketing of animal and human healthcare products primarily in India. It offers API products comprising fenbendazole toldimphos sodium cyromazine albendazole riclabendazole rafoxanide ornidazole ricobendazole oxfendazole closantel base closantel sodium nitroxynil halquinol and oxyclozanide as well as 26-diiodo-4-nitrophenol; and other API products such as anthelmintics. The company also provides animal feed ingredients including calcium iodate; and reagents for therapeutic use comprising potassium iodide. It also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai India.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
36.9%1 month
36.3%3 months
47.5%6 months
50.0%-
-
1.43
0.23
0.15
-13.02
1.52
-
-9.17M
399.96M
4.21M
-
-3.23
224.80
0.90
-20.22
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.27
Range1M
1.27
Range3M
3.33
Rel. volume
0.37
Price X volume
74.75K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
No data | |||||||
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sagardeep Alloys Limited | SAGARDEEP | Copper | 24.6 | 427.05M | -3.42% | 58.62 | 43.14% |
| Heads UP Ventures Limited | HEADSUP | Apparel Retail | 7.24 | 158.63M | 3.43% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -13.02 | 24.85 | Cheaper |
| Ent. to Revenue | 1.52 | 11.40 | Cheaper |
| PE Ratio | - | 51.36 | - |
| Price to Book | 1.43 | 6.83 | Cheaper |
| Dividend Yield | - | 0.52 | - |
| Std. Deviation (3M) | 47.46 | 42.17 | Par |
| Debt to Equity | 0.23 | 0.35 | Cheaper |
| Debt to Assets | 0.15 | 0.17 | Par |
| Market Cap | 399.96M | 290.82B | Emerging |